Dr. Marcus Wilson Discusses How Comparative Effectiveness Research is Used in the Managed Care Setting

The Orphan Drug Act in the Modern Drug Pricing Era

OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke risk across noncardioembolic subtypes without increasing major bleeding risk.

February 3rd 2026

Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Asundexian with standard antiplatelet therapy helped reduce the chances of a recurrent stroke without increasing the risk of bleeding, according to the OCEANIC-STROKE trial. | Image credit: Studio Multiverse - stock.adobe.com

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase.

January 27th 2026

How Apps and Wearable Tech Improve Life After Stroke: Shervin Badihian, MD

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

Closing Gaps in Stroke Care Starts With Defining the US Health Care Safety Net

Shervin Badihian, MD, explains how digital health tools can help boost poststroke activity via reminders, goals, feedback, and gamification.

Many solutions to improve disparities in stroke care come down to appropriate tailoring for the target system and community. | Image credit: BJP7images - stock.adobe.com

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

Clearer definitions, tailored programs and policies, and telestroke care could help close rural stroke care disparities.

Related Content

February 6th 2026

The Orphan Drug Act in the Modern Drug Pricing Era

OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke risk across noncardioembolic subtypes without increasing major bleeding risk.

February 3rd 2026

Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase.

January 27th 2026

How Apps and Wearable Tech Improve Life After Stroke: Shervin Badihian, MD

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

Closing Gaps in Stroke Care Starts With Defining the US Health Care Safety Net

Shervin Badihian, MD, explains how digital health tools can help boost poststroke activity via reminders, goals, feedback, and gamification.